We would love to hear your thoughts about our site and services, please take our survey here.
Short vol yesterday was nearly 32%,previous day 21%. We peaked at around $2.58, but finished at $2.13. The 'bot' is still operational. We now have some clarity re: main market listing, but think something positive on Foralumab will be the driver & reinforce/change sentiment.
Will be pleased to receive clarity on Accustem as think this will also have positive impact on the tils sp.
Profcheese has alluded to these. There is an oft expressed allusion that avct has provided timelines, so, to satisfy my curiousity, can anyone provide details of what they were, when they were advised & by what method (rns, video chat, etc) they were relayed to the shareholders. Thanks
Hants...definitely MY last post. Why indulge in pure speculation? It seems highly likely that over the 2-3 weeks all will be revealed. Either AVCT will have a test, or they won't. Whatever the outcome there will be jeering from either side of 'coin'.
ODX's board, or AVCT's board will be full of bloated &/or deflated egos. Personally, I don't care what ODX achieve, my interest is in Avacta, so am content to live or die with that, but I do find it odd that so many who clearly have no belief, or, probably, no investment, keep posting negative speculation, or just plain rubbish.
Anyway, as with MB, rip.
MB...affimers no good? Think quite a lot of research out there that proves they work. You obviously follow Avacta so will have read the quite recent links to both Bruker & Astra Zeneca re BAMS. On top of which both Moderna & LG Chem have extended collaborations with avct. I'm sure they wouldn't have done so had they not proved to be, at least, satisfactory.
Anyway, enough banter. RIP.
Your chairman was also delighted.. "I am delighted that we have received approval to sell the Mologic ELISA antibody test in India as this is a key target market. We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers. India is one of the fastest growing economies in the world and has a population of over 1.3 billion people. Clearly this is an important market for us to target and I look forward to updating shareholders on our commercial traction."
Presumeably won't end well.
hants/mb....."I am delighted with the excellent progress that has been made with BBI Solutions in developing a scalable version of a lateral flow rapid SARS-CoV-2 antigen test with sensitivity in the expected clinical range for spike protein. BBI Solutions is an excellent development partner and I am particularly pleased at how well the teams are working together to shorten the timeline as much as possible without compromising quality. "
That statement from AS in the last rns seems pretty clear to me. Why do you think it's not true?
According to Investing.com average daily volume(dv) some 312k. Only on 2 occasions since 1 Dec has the dv dropped below that. Shortiing has increased significantly since 4 Dec, & was 36% yesterday. Wow.
Whether one is in for long or short term the current trend is (very) uncomfortable. It will be interesting to see the impact the Foralumab news has on the sp. Can't help thinking there is an ulterior motive at play, but who knows. IMO the bod have certainly help create a degree of uncertaintity.
Ofcourse, the other quandry is Accustem. Not just initial value but how it will function as a business.
I've not followed this bb of late so all these (rhetorical) questions have probably been asked. Bit like navel gazing really until we get official news & not just a tv chat.
Sleepydave....agree, but official news is always the clincher. Too many conclusions have been reached on 'promising' situations that haven't materialised. In avacta's case much expectation has been built more by what has been desired & the joining of dots incorrectly, than by what we are/have been told by the Company.
In my case, I'm excited, but tempered accordingly.
Livedata..."A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples better than 300 pg/ml which is in the range expected for spike protein in clinical samples."
From the last rns. One must draw their own conclusion, but it seems pretty clear to me.
GMCC, interesting link to Moderna pipeline. I particularly notice mRNA-1893 for zika......avct did it's own work on that virus back in 2016. Moderna extended their licensing with us in Feb 2019 & '1893' entered a clinical trial on 30 july 2019.
Obviously can't draw any conclusions, but interesting.